Daily Itch Duration Linked to Quality-of-Life Burden

Overview

A study involving 522 patients with chronic pruritus found that daily itch duration is the strongest mediator between disease severity and quality of life (QoL). Other factors such as sleep disturbance and scratching frequency also contributed to QoL impairment.

Background

Chronic pruritus is a prevalent symptom in dermatology, significantly affecting patients' quality of life. Understanding the relationship between itch-related variables and disease severity is crucial.

Data Highlights

No numerical data available in the source material.

Key Findings

• Daily itch duration was identified as the strongest mediator of the association between disease severity and QoL.
• Sleep disturbance, scratching frequency, and average itch intensity also mediated this relationship.
• Impaired QoL correlated more strongly with itch-related measures than with overall disease severity.
• Female sex and moderate disease severity were independently associated with greater QoL impairment.
• Patients with atopic dermatitis, chronic prurigo, and chronic urticaria experienced higher QoL impairment compared to those with psoriasis.

Clinical Implications

Evaluating daily itch duration, alongside other itch-related factors, may provide a better understanding of how disease severity impacts quality of life.

Conclusion

The findings highlight the importance of assessing itch in chronic inflammatory skin diseases.

Related Resources & Content

1. Pereira MP, et al., Dermatology and Therapy, 2023 -- Daily Itch Duration Linked to Quality-of-Life Burden
2. Dermatology and Therapy (Springer) — Beyond the Skin: Assessing Itch in Atopic Dermatitis – Insights from UK Dermatologists. A Cross-Sectional Survey and Narrative Review
3. Optometric Management — Wicked Itch of the West
4. MDSpire News — AD Itch: A Ten-Year Overview
5. European S2k Guideline on Chronic Pruritus
6. Clinical Guidelines on Dermatology and Venereology | EADV
7. The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria - PubMed
8. Novel Drug Approvals for 2024 | FDA
9. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials - PMC
10. New and Emerging Pharmacotherapies for Pruritus: A Systematic Review and Network Meta-Analysis - PubMed
11. Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study - PubMed
12. Impact of Chronic Nodular Prurigo on Quality of Life: A Systematic Review of the Literature - PubMed